Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
These are not sterile
Peptide therapy is part of a broader longevity-and-aesthetics framework that includes IV therapy, advanced facials, injectables, laser treatments, and skin rejuvenation
Melittin-treated mice demonstrate less neuronal loss in the spinal cord and better motor control, which enhances motor performance
How ProHealth Longevity Approaches Testing and Quality In the BPC-157 supplement market, quality verification matters more than in almost any other supplement category
